Pharmacogenetics of сlozapine: toward personalized therapy in treatment resistant schizophrenia

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Clozapine is recognized as the most effective medication for treatment-resistant schizophrenia (TRS). However, the use of clozapine in clinical practice remains limited due to challenges related to its efficacy and safety. Pharmacogenetics may help enhance both the effectiveness and safety of its use.

Aims — to analyze the role of polymorphic variants in genes associated with pharmacogenetic factors in the development of adverse reactions and the efficacy of clozapine therapy.

Methods. We conducted a prospective pharmacogenetic study of the efficacy and safety of clozapine in patients with TRS (F20 according to ICD-10). The observation period was 28 ± 3 days. The primary endpoint was the change in the severity of psychopathological symptoms, assessed using the PANSS, CGI-S, and CGI-I scales. Treatment safety was evaluated using the UKU Side Effect Rating Scale. Genotyping was performed using the real-time PCR method.

Results. The study included 61 patient receiving treatment in a psychiatric inpatient facility. According to our data, clozapine efficacy was associated with CYP2C9 rs1799853, DRD4 rs1800955, and ABCB1 rs1128503. The final clozapine dose was influenced by ABCB1 rs1045642, rs2032582, and rs1128503. Associations with safety were identified for CYP2D6 rs3892097 and rs1065852; CYP2D6 rs3892097; CYP2C19 rs4244285; CYP2C9 rs1057910; CYP3A4 rs2740574; CYP2C19 rs12248560; ABCB1 rs1045642, rs2032582, and rs1128503; HTR2A rs6313; DRD2 rs1800497 and DRD4 rs1800955.

Conclusions. Our study revealed considerable interindividual variability in clozapine treatment outcomes among patients with TRS. Polymorphisms CYP2C9 and DRD4 were associated with improvements in negative symptoms, while ABCB1 variants showed the strongest impact, influencing both final clozapine dose and tolerability. Additional associations with CYP2D6, CYP2C19, CYP3A4, HTR2A, and DRD2 were observed for adverse drug reactions such as sedation, weight gain, memory impairment, and depression. These findings highlight the importance of pharmacogenetic profiling in optimizing clozapine therapy, though replication in larger and ethnically diverse cohorts remains necessary.

Full Text

Restricted Access

About the authors

Dmitriy N. Sosin

Mental-health Clinic No. 1 named after N.A. Alexeev; Russian Research Center of Surgery Named after Academician B.V. Petrovsky

Author for correspondence.
Email: sosin.dmitriy@gmail.com
ORCID iD: 0000-0002-2314-7174
SPIN-code: 6783-7981

MD, PhD, Assistant Professor

Russian Federation, Moscow; Moscow

Aiperi K. Khasanova

Russian Medical Academy of Continuous Professional Education

Email: abdyrahmanova_peri@mail.ru
ORCID iD: 0000-0001-5391-0786
SPIN-code: 5534-2860

MD, psychiatrist

Russian Federation, Moscow

Svetlana N. Tuchkova

Russian Research Center of Surgery Named after Academician B.V. Petrovsky; Russian Medical Academy of Continuous Professional Education

Email: svetlana.tuch1998@gmail.com
ORCID iD: 0009-0001-2744-2752
SPIN-code: 6807-3210

Molecular Biologist

Russian Federation, Moscow; Moscow

Alexandr S. Rusanov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: alexrus146@yandex.ru
ORCID iD: 0000-0002-0658-9130
SPIN-code: 4785-2353

MD, PhD

Russian Federation, Моscow

Yuri S. Bellevich

Russian Medical Academy of Continuous Professional Education

Email: urabel121@yandex.ru
ORCID iD: 0009-0000-5996-8575
SPIN-code: 7896-2034

MD, psychiatrist

Russian Federation, Moscow

Anastasia G. Kirova

Russian Medical Academy of Continuous Professional Education

Email: nast.kirova@yandex.ru
ORCID iD: 0000-0003-4263-6640
SPIN-code: 3386-5900

MD, psychiatrist

Russian Federation, Moscow

Sergey N. Mosolov

Russian Medical Academy of Continuous Professional Education; Moscow Research Institute of Psychiatry — Branch of the Serbsky National Medical Research Centre for Psychiatry and Narcology

Email: profmosolov@mail.ru
ORCID iD: 0000-0002-5749-3964
SPIN-code: 3009-9162

MD, PhD, Professor

Russian Federation, Moscow; Moscow

Dmitry A. Sychev

Russian Research Center of Surgery Named after Academician B.V. Petrovsky; Russian Medical Academy of Continuous Professional Education

Email: dmitry.alex.sychev@gmail.com
ORCID iD: 0000-0002-4496-3680
SPIN-code: 4525-7556

MD, PhD, Professor, Professor of the RAS, Academician of the RAS

Russian Federation, Moscow; Moscow

References

  1. Świtaj P, Anczewska M, Chrostek A, et al. Disability and schizophrenia: A systematic review of experienced psychosocial difficulties. BMC Psychiatry. 2012;12:193. doi: https://doi.org/10.1186/1471-244X-12-193
  2. Correll CU, Agid O, Crespo-Facorro B, et al. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia. CNS Drugs. 2022;36(7):659–679. doi: https://doi.org/10.1007/s40263-022-00932-2
  3. Mizuno Y, McCutcheon RA, Brugger SP, et al. Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. Neuropsychopharmacology. 2020;45(4):622–631. doi: https://doi.org/10.1038/s41386-019-0577-3
  4. Хасанова А.К., Коврижных И.В., Мосолов С.Н. Антисуицидальный эффект клозапина (алгоритм назначения и клинического мониторинга) // Современная терапия психических расстройств. — 2023. — № 4. — С. 48–63. [Khasanova AK, Kovrizhnykh IV, Mosolov SN. Antisuicidal effect of clozapine (prescribing algorithm and clinical monitoring). Sovrem ter psih rasstrojstv [Current Therapy of Mental Disorders]. 2023;4:48–63. (In Russ.)] doi: https://doi.org/10.21265/PSYPH.2023.31.74.005
  5. Siskind D, McCartney L, Goldschlager R, et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2016;209(5):385–392. doi: https://doi.org/10.1192/bjp.bp.115.177261
  6. Correll CU, Solmi M, Croatto G, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248–271. doi: https://doi.org/10.1002/wps.20994
  7. Seppälä A, Pylvänäinen J, Lehtiniemi H, et al. Predictors of response to pharmacological treatments in treatment-resistant schizophrenia — a systematic review and meta-analysis. Schizophr Res. 2021;236:123–134. doi: https://doi.org/10.1016/j.schres.2021.08.005
  8. Baptista T, Serrano A, Presti APL, et al. Clozapine safety monitoring and related research in psychiatry and neurology in South America: A scoping review. Schizophr Res. 2024;268:29–33. doi: https://doi.org/10.1016/j.schres.2023.07.029
  9. Кирилочев О.О. Осложнения терапии клозапином: актуализация информации // Современная терапия психических расстройств. — 2023. — № 3. — С. 12–20. [Kirilochev OO. Complications of clozapine treatment: update of information. Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. 2023;3:12–20. (In Russ.)] doi: https://doi.org/10.21265/PSYPH.2023.11.37.002
  10. Fernandez-Egea E, Flanagan RJ, Taylor D, et al. Mortality associated with clozapine: what is the evidence? Br J Psychiatry. 2024;225(3):357–359. doi: https://doi.org/10.1192/bjp.2024.88
  11. Khasanova AK, Sosin DN, Mosolov SN, et al. Polymorphisms of the HTR2C Gene as Predictors of Metabolic Disturbances During Clozapine Therapy: A Systematic Review and Meta-Analysis. J Clin Med. 2025;14(11):3861. doi: https://doi.org/10.3390/jcm14113861
  12. Tiihonen J, Tanskanen A, Mittendorfer-Rutz E, et al. Effectiveness of clozapine augmentation with specific doses of other antipsychotics in schizophrenia: a meta-analysis from two nationwide cohorts. World Psychiatry. 2025;24(2):250–259. doi: https://doi.org/10.1002/wps.21316
  13. Sangüesa E, Fernández-Egea E, Concha J, et al. Impact of Pharmacogenetic Testing on Clozapine Treatment Efficacy in Patients with Treatment-Resistant Schizophrenia. Biomedicines. 2024;12(3):597. doi: https://doi.org/10.3390/biomedicines12030597
  14. Dean L, Kane M. Clozapine Therapy and CYP Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
  15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33;quiz 34–57.
  16. Aboraya A, Nasrallah HA. Perspectives on the Positive and Negative Syndrome Scale (PANSS): Use, misuse, drawbacks, and a new alternative for schizophrenia research. Ann Clin Psychiatry. 2016;28(2):125–131.
  17. Khan A, Khan SR, Shankles EB, et al. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol. 2002;17(6):281–285. doi: https://doi.org/10.1097/00004850-200211000-00003
  18. Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand. 2000;101(4):323–329.
  19. Schouby Bock M, Nørgaard Van Achter O, Dines D, et al. Clinical validation of the self-reported Glasgow Antipsychotic Side-effect Scale using the clinician-rated UKU side-effect scale as gold standard reference. J Psychopharmacol. 2020;34(8):820–828. doi: https://doi.org/10.1177/0269881120916122
  20. Naveen M, Patil AN, Pattanaik S, et al. ABCB1 and DRD3 polymorphism as a response predicting biomarker and tool for pharmacogenetically guided clozapine dosing in Asian Indian treatment resistant schizophrenia patients. Asian J Psychiatr. 2020;48:101918. doi: https://doi.org/10.1016/j.ajp.2019.101918
  21. Albitar O, Harun SN, Sheikh Ghadzi SM. Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics. CNS Drugs. 2024;38(7):571–581. doi: https://doi.org/10.1007/s40263-024-01092-1
  22. Piatkov I, Caetano D, Assur Y, et al. ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med. 2017;10:235–242. doi: https://doi.org/10.2147/PGPM.S142314
  23. Wang Y, Tan X, Chen Z, et al. Association between the rs6313 polymorphism in the 5-HTR2A gene and the efficacy of antipsychotic drugs. BMC Psychiatry. 2023;23(1):682. doi: https://doi.org/10.1186/s12888-023-05165-1
  24. Park SI, Kim S, Park K, et al. Predictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia. PLoS One. 2025;20(3):e0319037. doi: https://doi.org/10.1371/journal.pone.0319037
  25. Rajagopal VM, Rajkumar AP, Jacob KS, et al. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenet Genomics. 2018;28(1):31–35. doi: https://doi.org/10.1097/FPC.0000000000000314
  26. Leung JG, Zhang L, Markota M, et al. A systematic review of clozapine‐associated inflammation and related monitoring. Pharmacotherapy. 2023;43(12):1364–1396. doi: https://doi.org/10.1002/phar.2887
  27. Lesche D, Mostafa S, Everall I, et al. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharmacogenomics J. 2020;20(2):192–201. doi: https://doi.org/10.1038/s41397-019-0108-y
  28. Amin ML. P-glycoprotein Inhibition for Optimal Drug Delivery. Drug Target Insights. 2013;7:27–34. doi: https://doi.org/10.4137/DTI.S12519
  29. Su J, Leerkes EM, Augustine ME. DRD4 interacts with adverse life events in predicting maternal sensitivity via emotion regulation. J Fam Psychol. 2018;32(6):783–792. doi: https://doi.org/10.1037/fam0000454
  30. Horton CL. The neurocognition of dreaming: key questions and foci. Emerg Top Life Sci. 2023;7(5):477–486. doi: https://doi.org/10.1042/ETLS20230099
  31. Morrison PD, Jauhar S, Young AH. The mechanism of action of clozapine. J Psychopharmacol. 2025;39(4):297–300. doi: https://doi.org/10.1177/02698811251319458
  32. López-Echeverri YP, Cardona-Londoño KJ, Garcia-Aguirre JF, et al. Effects of serotonin transporter and receptor polymorphisms on depression. Rev Colomb Psiquiatr (Engl Ed). 2023;52(2):130–138. doi: https://doi.org/10.1016/j.rcpeng.2021.07.003
  33. Li M, Wang H, Li J, et al. Peer victimization, depression, and non-suicidal self-injury among Chinese adolescents: the moderating role of the 5-HTR2A gene rs6313 polymorphism. Child Adolesc Psychiatry Ment Health. 2022;16(1):108. doi: https://doi.org/10.1186/s13034-022-00532-4
  34. Stahl SM, Grady MM, Muntner N. Stahl’s Essential Psychopharmacology : Prescriber’s Guide. Cambridge University Press; 2021.
  35. Sachau J, Bruckmueller H, Gierthmühlen J, et al. The serotonin receptor 2A (HTR2A) rs6313 variant is associated with higher ongoing pain and signs of central sensitization in neuropathic pain patients. Eur J Pain. 2021;25(3):595–611. doi: https://doi.org/10.1002/ejp.1696
  36. Grover S, Sahoo S. Clozapine induced akathisia: A case report and review of the evidence. Indian J Pharmacol. 2015;47(2):234–235. doi: https://doi.org/10.4103/0253-7613.153441
  37. Gerolymos C, Barazer R, Yon D.K, et al. Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia. JAMA Netw Open. 2024;7(3):e241527. doi: https://doi.org/10.1001/jamanetworkopen.2024.1527
  38. Kandra K. Aripiprazole- and Lurasidone-Induced Akathisia: A Case Report and Literature Review. Cureus. 2025;17(9):e92704. doi: https://doi.org/10.7759/cureus.92704
  39. Wu H, Siafis S, Wang D, et al. Antipsychotic-induced akathisia in adults with acute schizophrenia: A systematic review and dose-response meta-analysis. Eur Neuropsychopharmacol. 2023;72:40–49. doi: https://doi.org/10.1016/j.euroneuro.2023.03.015
  40. D’Souza RS, Aslam SP, Hooten WM. Extrapyramidal Side Effects. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
  41. Patel J, Marwaha R. Akathisia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 "Paediatrician" Publishers LLC